Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer

Changhoon Yoo, Sung Bae Kim, Jungsil Ro, Seock Ah Im, Young Hyuck Im, Jee Hyun Kim, Jin Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyuncheol Chung

Research output: Contribution to journalArticle

Abstract

Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p <.001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.

Original languageEnglish
Pages (from-to)499-507
Number of pages9
JournalCancer Research and Treatment
Volume48
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

docetaxel
Angiogenesis Inhibitors
Biomarkers
Breast Neoplasms
Disease-Free Survival
C-Reactive Protein
Vascular Endothelial Growth Factor A
Interleukin-6
Platelet-Derived Growth Factor
Fibroblast Growth Factors
5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yoo, Changhoon ; Kim, Sung Bae ; Ro, Jungsil ; Im, Seock Ah ; Im, Young Hyuck ; Kim, Jee Hyun ; Ahn, Jin Hee ; Jung, Kyung Hae ; Song, Hong Suk ; Kang, Seok Yun ; Park, Hee Sook ; Chung, Hyuncheol. / Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer. In: Cancer Research and Treatment. 2016 ; Vol. 48, No. 2. pp. 499-507.
@article{06e800529c55468ebdc7bae81f8bf825,
title = "Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer",
abstract = "Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p <.001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.",
author = "Changhoon Yoo and Kim, {Sung Bae} and Jungsil Ro and Im, {Seock Ah} and Im, {Young Hyuck} and Kim, {Jee Hyun} and Ahn, {Jin Hee} and Jung, {Kyung Hae} and Song, {Hong Suk} and Kang, {Seok Yun} and Park, {Hee Sook} and Hyuncheol Chung",
year = "2016",
month = "4",
day = "1",
doi = "10.4143/crt.2015.089",
language = "English",
volume = "48",
pages = "499--507",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "2",

}

Yoo, C, Kim, SB, Ro, J, Im, SA, Im, YH, Kim, JH, Ahn, JH, Jung, KH, Song, HS, Kang, SY, Park, HS & Chung, H 2016, 'Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer', Cancer Research and Treatment, vol. 48, no. 2, pp. 499-507. https://doi.org/10.4143/crt.2015.089

Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer. / Yoo, Changhoon; Kim, Sung Bae; Ro, Jungsil; Im, Seock Ah; Im, Young Hyuck; Kim, Jee Hyun; Ahn, Jin Hee; Jung, Kyung Hae; Song, Hong Suk; Kang, Seok Yun; Park, Hee Sook; Chung, Hyuncheol.

In: Cancer Research and Treatment, Vol. 48, No. 2, 01.04.2016, p. 499-507.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer

AU - Yoo, Changhoon

AU - Kim, Sung Bae

AU - Ro, Jungsil

AU - Im, Seock Ah

AU - Im, Young Hyuck

AU - Kim, Jee Hyun

AU - Ahn, Jin Hee

AU - Jung, Kyung Hae

AU - Song, Hong Suk

AU - Kang, Seok Yun

AU - Park, Hee Sook

AU - Chung, Hyuncheol

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p <.001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.

AB - Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p <.001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.

UR - http://www.scopus.com/inward/record.url?scp=84963811913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963811913&partnerID=8YFLogxK

U2 - 10.4143/crt.2015.089

DO - 10.4143/crt.2015.089

M3 - Article

C2 - 26194374

AN - SCOPUS:84963811913

VL - 48

SP - 499

EP - 507

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -